pharma · Attention Deficit Disorder With Hyperactivity · Hidradenitis suppurativa (HS) · AVTX
Avalo Therapeutics
Avalo Therapeutics patent portfolio — 10 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- 1500 Liberty Ridge Dr, Chesterbrook, Pennsylvania 19087, US
- Founded
- 2011
- Employees
- 48
- Programs
- 17
- Drugs
- 2
- Patents
- 10
Avalo Therapeutics patents
10 pharmaceutical patents indexed for Avalo Therapeutics. 0 expire within 24 months.
Avalo Therapeutics has 10 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12410153
Compounds, compositions and methods
granted -
US 12331107
Methods of treating pneumonia or respiratory failure associated with COVID-19 by administering an anti-LIGHT antibody
granted -
US 11939368
QTY Fc fusion receptor proteins
granted -
US 11898180
Compositions and methods for amino acid depletion therapy
granted -
US 11850243
Dihydropyridine compositions and methods for treating neurological disorders
granted -
US 11708406
Method of treating acute respiratory distress syndrome (ARDS) or acute lung injury (ALI) associate with COVID-19 by administering an anti-LIGHT antibody
granted -
US 11555060
QTY FC fusion water soluble receptor proteins
granted -
US 11479576
Nucleic acid prodrugs
granted -
US 11401320
QTY FC fusion receptor proteins
granted -
US 7563777
Method to induce neovascular formation and tissue regeneration
granted
Frequently asked questions
How many patents does Avalo Therapeutics have?
10 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Avalo Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.